---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-333834"
form_type: "8-K"
ticker: "KYMR"
cik: "0001815442"
company_name: "Kymera Therapeutics, Inc."
filed_at: "2026-08-05T11:10:14+00:00"
generated_at: "2026-08-05T11:15:29.280560+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Kymera Q2 net loss narrows to $61.2M; KT-621 AD trial data accelerated to year-end 2026

## Summary
- Net loss of $61.2M vs $76.6M in Q2 2025; collaboration revenue of $65.0M from Gilead ($45M) and Sanofi ($20M) milestones.
- Cash of $1.5B as of June 30, 2026, providing runway into 2029.
- KT-621 Phase 2b AD trial enrollment completed ~6 months early; topline data now expected by year-end 2026 (vs mid-2027).
- KT-579 Phase 1 healthy volunteer data expected 4Q26; lupus proof-of-concept trial planned.
- Appointed Felix Baker as Chairman, Terence Rooney as CMO; Sanofi initiated KT-485 Phase 1.

## SEC filing metadata
- accession: 0001193125-26-333834
- form_type: 8-K
- ticker: KYMR
- cik: 0001815442
- company_name: Kymera Therapeutics, Inc.
- filed_at: 2026-08-05T11:10:14+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815442/000119312526333834/0001193125-26-333834-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815442/000119312526333834/kymr-20260805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-333834
- JSON: https://secwatch.observer/filing/0001193125-26-333834.json
- Plain text: https://secwatch.observer/filing/0001193125-26-333834.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.